Insider Selling: Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $10,036.04 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) EVP Eliana Clark sold 1,022 shares of Intellia Therapeutics stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $9.82, for a total value of $10,036.04. Following the completion of the sale, the executive vice president directly owned 95,369 shares in the company, valued at $936,523.58. This represents a 1.06% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Intellia Therapeutics Stock Performance

NASDAQ NTLA traded down $0.02 during mid-day trading on Thursday, reaching $10.72. 2,811,328 shares of the stock were exchanged, compared to its average volume of 2,963,793. The stock has a market capitalization of $1.11 billion, a PE ratio of -2.05 and a beta of 2.21. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $28.18. The business's fifty day simple moving average is $8.73 and its 200 day simple moving average is $9.40.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. The company had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The business's revenue for the quarter was down 42.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.12) EPS. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Citigroup decreased their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Chardan Capital restated a "buy" rating and set a $68.00 target price on shares of Intellia Therapeutics in a research report on Friday, May 9th. Guggenheim dropped their target price on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a report on Monday, May 12th. Canaccord Genuity Group lowered their price target on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a report on Tuesday, June 3rd. Finally, Wedbush reaffirmed a "neutral" rating and issued a $7.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 16th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $33.37.

Institutional Trading of Intellia Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Ensign Peak Advisors Inc increased its stake in shares of Intellia Therapeutics by 2.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock valued at $457,000 after acquiring an additional 1,100 shares during the last quarter. HighTower Advisors LLC grew its holdings in Intellia Therapeutics by 8.2% in the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company's stock valued at $120,000 after purchasing an additional 1,282 shares during the period. Arizona State Retirement System increased its position in Intellia Therapeutics by 6.1% during the fourth quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock worth $327,000 after purchasing an additional 1,615 shares during the last quarter. E Fund Management Co. Ltd. raised its stake in Intellia Therapeutics by 10.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company's stock worth $210,000 after purchasing an additional 1,634 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its stake in Intellia Therapeutics by 56.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock worth $33,000 after purchasing an additional 1,655 shares during the period. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.